MANSFIELD – Medical device maker Covidien LLC’s pharmaceutical arm, Mallinckrodt, has entered into a definitive agreement to acquire St. Paul, Minn.-based CNS Therapeutics Inc.
CNS, a privately help specialty pharmaceutical company, focuses on developing and commercializing products for site-specific administration to the central nervous system for the treatment of neurological disorders and chronic pain.
Mallinckrodt will acquire all outstanding capital stock from CNS for roughly $100 million. The deal is expected to close during the fourth quarter of 2012.
“This acquisition supports our strategy of leveraging our therapeutic expertise and our core capabilities in manufacturing, regulatory and commercialization to serve patients,” Mark Trudeau, president of pharmaceuticals, said in a statement.
“CNS Therapeutics’ marketed product line complements our branded portfolio,” added Trudeau. “Their central nervous system and pain management products in development complement our pipeline and address an important need for patients.”
Currently, Mallinckrodt is the largest supplier of opiod pain medications in the U.S. and among the top 10 generic pharmaceutical manufacturers in the country, based on prescriptions, according to Covidien.
Covidien announced plans in December to spin off Mallinckrodt into a stand-alone company. The process is expected to be completed mid-2013.
Join PBN and two panels of successful female executives, business owners and entrepreneurs as we delve into what women should do to advance their careers, and become leaders in the corporate world and their own enterprises.
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.